Related Experiment Video
Updated: Jun 24, 2026
07:15
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Common variants at ten loci modulate the QT interval duration in the QTSCD Study
Arne Pfeufer1, Serena Sanna, Dan E Arking
1Institute of Human Genetics, Helmholtz Center Munich, Germany. arne.pfeufer@helmholtz-muenchen.de
Nature Genetics
|March 24, 2009
Summary
Genetic analysis of 15,842 individuals identified new genes linked to cardiac repolarization, potentially impacting ventricular arrhythmias and sudden cardiac death (SCD). These findings advance our understanding of heart rhythm disorders.
Area of Science:
- Cardiovascular Genetics
- Human Genomics
- Molecular Cardiology
Background:
- The QT interval reflects cardiac repolarization and is crucial for preventing ventricular arrhythmias and sudden cardiac death (SCD).
- Genetic variants, such as those in NOS1AP, are known to influence cardiac repolarization.
- Identifying genetic factors affecting the QT interval is vital for understanding and managing cardiac electrophysiology disorders.
Purpose of the Study:
- To confirm the association of NOS1AP with QT interval duration.
- To identify novel genetic loci associated with QT interval variation.
- To discover new candidate genes contributing to ventricular arrhythmias and SCD risk.
Main Methods:
- Genome-wide association study (GWAS) analysis.
- Utilized data from five large, population-based cohorts (ARIC, KORA, SardiNIA, GenNOVA, HNR) comprising 15,842 individuals of European ancestry.
- Statistical analysis to identify genetic loci associated with QT interval duration at a genome-wide significance threshold (P < 5 x 10(-8)).
Main Results:
- Confirmed the association between NOS1AP variants and QT interval duration.
- Identified nine additional genetic loci significantly associated with QT interval duration.
- Four identified loci are located near known monogenic long-QT syndrome genes (KCNQ1, KCNH2, SCN5A, KCNJ2).
- Other identified loci include genes with established electrophysiological roles (ATP1B1, PLN) and novel genes (RNF207, near LITAF, within NDRG4-GINS3-SETD6-CNOT1) not previously linked to cardiac electrophysiology.
Conclusions:
- This study significantly expands the landscape of genes influencing cardiac repolarization and QT interval duration.
- The identified novel loci and genes provide new targets for investigating the mechanisms underlying ventricular arrhythmias and sudden cardiac death.
- Findings contribute to a deeper understanding of the genetic architecture of cardiac electrophysiology and SCD risk.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
02:26Comparing Copy Number Variations and SNPs
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...